Shanghai Pharmaceuticals Publishes Audited 2025 Annual Results

Shanghai Pharmaceuticals Holding Co ( (HK:2607) ) has provided an update.

Shanghai Pharmaceuticals Holding Co., Ltd. has released its audited annual results for the year ended 31 December 2025, prepared under China Accounting Standards and reviewed by its board audit committee. The full 2025 annual report will be made available in due course on the websites of the Hong Kong Stock Exchange and the company, providing investors and other stakeholders with detailed financial and operational disclosures.

The announcement, approved by chairman Yang Qiuhua and listing the current board composition, underscores the group’s ongoing corporate governance transparency as it communicates its performance to the market. By reiterating its vision, mission and core values, the company reinforces its strategic identity as a leading branded pharmaceutical manufacturer and healthcare service provider in China, signaling continuity in long-term positioning and stakeholder focus.

The most recent analyst rating on (HK:2607) stock is a Hold with a HK$13.00 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.

More about Shanghai Pharmaceuticals Holding Co

Shanghai Pharmaceuticals Holding Co., Ltd. is a PRC-incorporated joint stock company in the pharmaceutical and healthcare sector, focusing on the manufacture of branded medicines and the provision of healthcare services. The group positions itself as a respected drug maker with strong industry reputation and is committed to improving people’s quality of healthy living through innovation and responsible operations.

YTD Price Performance: 0.70%

Average Trading Volume: 2,216,670

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$63.3B

See more data about 2607 stock on TipRanks’ Stock Analysis page.